Financings

bluebird bio Inc. closed a $60 million series D financing for its clinical program on adrenoleukodystrophy.

Hyperion Therapeutics Inc. priced its IPO offering of 5 million shares at $10 per share.

Histogenics Corp. completed a $49 million financing for its Phase III trial on a neocartilage tissue implant.

Anthera Pharmaceuticals Inc. raised $33 million in a public offering, selling 33 million shares at $1 each.

PTC Therapeutics Inc. raised $30 million to support late-stage clinical development of its drug ataluren.

Cell Medica Ltd. has raised $26.5 million in both public and private funding.

Deals

Nuvo Research Inc. will receive $6 million in milestone payments from its partner Galderma SA.

Synergy Pharmaceuticals Inc. is acquiring Callisto Pharmaceuticals Inc. in an all-share deal.

Sandoz Inc. completed its acquisition of U.S. dermatology company Fougera Pharmaceuticals Inc.

Chimerix Inc. granted Merck & Co. Inc. rights to CMX157 currently in development to treat HIV infection.

. . . And More

See BioWorld Today for coverage of the XIX International AIDS Conference

Onyx Pharmaceuticals Inc. won accelerated approval for multiple myeloma drug Kyprolis (carfilzomib).

Amarin Corp. received FDA approval for Vascepa (icosapent ethyl) capsules to reduce high triglyceride levels.

Advanced BioHealing Inc. has changed its name to Shire Regenerative Medicine Inc.